[1] |
Trautinger F. Phototherapy of cutaneous T⁃cell lymphomas[J]. Photochem Photobiol Sci, 2018,17(12):1904⁃1912. doi: 10.1039/ c8pp00170g.
|
[2] |
Vieyra⁃Garcia P, Wolf P. Psoralen⁃ultraviolet a maintenance in mycosis fungoides: the underlying question[J]. Br J Dermatol, 2017,177(2):336⁃337. doi: 10.1111/bjd.15670.
|
[3] |
Nikolaou V, Sachlas A, Papadavid E, et al. Phototherapy as a first⁃line treatment for early⁃stage mycosis fungoides: the results of a large retrospective analysis[J]. Photodermatol Photoimmunol Photomed, 2018,34(5):307⁃313. doi: 10.1111/phpp.12383.
|
[4] |
Abo Elnazar SY, Ghazy AA, Ghoneim HE, et al. Effect of ultra violet irradiation on the interplay between Th1 and Th2 lymphocytes[J]. Front Pharmacol, 2015,6:56. doi: 10.3389/fphar. 2015.00056.
|
[5] |
Pavlotsky F, Dawood M, Barzilai A. Potential of narrow⁃band ultraviolet B to induce sustained durable complete remission off⁃therapy in patients with stage I mycosis fungoides[J]. J Am Acad Dermatol, 2019,80(6):1550⁃1555. doi: 10.1016/j.jaad.2018.05. 023.
|
[6] |
Edelson R, Wu Y, Schneiderman J. American council on ECP (ACE): why now?[J]. J Clin Apher, 2018,33(4):464⁃468. doi: 10.1002/jca.21627.
|
[7] |
Quaglino P, Knobler R, Fierro MT, et al. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T⁃cell lymphoma: a single center clinical experience with long⁃term follow⁃up data and a brief overview of the literature[J]. Int J Dermatol, 2013,52(11):1308⁃1318. doi: 10.1111/ijd.12121.
|
[8] |
Atilla E, Atilla PA, Bozdag SC, et al. Extracorporeal photochemotherapy in mycosis fungoides[J]. Transfus Clin Biol, 2017,24(4):454⁃457. doi: 10.1016/j.tracli.2017.05.001.
|
[9] |
Pileri A, Sgubbi P, Agostinelli C, et al. Photodynamic therapy: an option in mycosis fungoides[J]. Photodiagnosis Photodyn Ther, 2017,20:107⁃110. doi: 10.1016/j.pdpdt.2017.09.004.
|
[10] |
Polańska A, Osmola⁃Mańkowska A, Olek⁃Hrab K, et al. High⁃frequency ultrasonography in objective evaluation of the efficacy of PUVA and UVA 1 phototherapy in mycosis fungoides[J]. Arch Dermatol Res, 2017,309(8):645⁃651. doi: 10.1007/s00403⁃017⁃1767⁃7.
|
[11] |
Adışen E, Tektaş V, Erduran F, et al. Ultraviolet A1 phototherapy in the treatment of early mycosis fungoides[J]. Dermatology, 2017,233(2⁃3):192⁃198. doi: 10.1159/000458149.
|
[12] |
Specchio F, Carboni I, Cannarozzo G, et al. Excimer UV radiation in dermatology[J]. Int J Immunopathol Pharmacol, 2014,27(2):287⁃289. doi: 10.1177/039463201402700217.
|
[13] |
Deaver D, Cauthen A, Cohen G, et al. Excimer laser in the treatment of mycosis fungoides[J]. J Am Acad Dermatol, 2014,70(6):1058⁃1060. doi: 10.1016/j.jaad.2014.01.915.
|
[14] |
Rupoli S, Canafoglia L, Goteri G, et al. Results of a prospective phase II trial with oral low⁃dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides[J]. Eur J Dermatol, 2016,26(1):13⁃20. doi: 10.1684/ejd.2015.2672.
|
[15] |
Humme D, Nast A, Erdmann R, et al. Systematic review of combination therapies for mycosis fungoides[J]. Cancer Treat Rev, 2014,40(8):927⁃933. doi: 10.1016/j.ctrv.2014.06.005.
|
[16] |
Salva KA, Wood GS. Epigenetically enhanced photodynamic therapy (ePDT) is superior to conventional photodynamic therapy for inducing apoptosis in cutaneous T⁃cell lymphoma[J]. Photochem Photobiol, 2015,91(6):1444⁃1451. doi: 10.1111/ php.12521.
|
[17] |
Gökdemir G, Barutcuoglu B, Sakiz D, et al. Narrowband UVB phototherapy for early⁃stage mycosis fungoides: evaluation of clinical and histopathological changes[J]. J Eur Acad Dermatol Venereol, 2006,20(7):804⁃809. doi: 10.1111/j.1468⁃3083.2006. 01635.x.
|
[18] |
Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome ⁃ Update 2017[J]. Eur J Cancer, 2017,77:57⁃74. doi: 10.1016/j.ejca.2017. 02.027.
|
[19] |
Fernández⁃de⁃Misa R, Hernández⁃Machín B, Servitje O, et al. First⁃line treatment in lymphomatoid papulosis: a retrospective multicentre study[J]. Clin Exp Dermatol, 2018,43(2):137⁃143. doi: 10.1111/ced.13256.
|
[20] |
Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium[J]. J Am Acad Dermatol, 2016,74(1):27⁃58. doi: 10.1016/j.jaad.2015.09.033.
|
[21] |
Bulur I, Erdogan HK, Aksu AE, et al. The efficacy and safety of phototherapy in geriatric patients: a retrospective study[J]. An Bras Dermatol, 2018,93(1):33⁃38. doi: 10.1590/abd1806⁃4841. 20185468.
|
[22] |
Laws PM, Shear NH, Pope E. Childhood mycosis fungoides: experience of 28 patients and response to phototherapy[J]. Pediatr Dermatol, 2014,31(4):459⁃464. doi: 10.1111/pde.12338.
|
[23] |
Sánchez MA, González T, Gaitán MF, et al. Is PUVA maintenance therapy necessary in patients with early⁃stage mycosis fungoides? Evaluation of a treatment guideline over a 28⁃month follow⁃up[J]. Int J Dermatol, 2011,50(9):1086⁃1093. doi: 10.1111/j.1365⁃4632.2010.04833.x.
|
[24] |
Trautinger F. Phototherapy of mycosis fungoides[J]. G Ital Dermatol Venereol, 2017,152(6):597⁃606. doi: 10.23736/S0392⁃0488.17.05737⁃6.
|
[25] |
Hoot JW, Wang L, Kho T, et al. The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides[J]. J Dermatolog Treat, 2018,29(3):272⁃276. doi: 10.1080/09546634.2017.1365113.
|